Skip to content

诚信健康

US · ELV #242 按市值排名 上市于 1970
428.26 -0.17 -0.04%
实时 - 追踪5344个代码 - 心跳于444秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了0.1个百分点。

机构持股

机构持股比例
95.57% -0.12pp
机构数量
1,905 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund81.50%
Public Company3.32%
Hedge Fund3.30%
Government Pension Fund2.30%
Private Company2.21%
Sovereign Wealth Fund1.92%
Insurance Company0.48%
Family Office/Trust0.16%
VC/PE Fund0.13%
Individual/Insider0.12%
Other4.69%

主要股东 截至 2026-06-30

BlackRock 8.76% · 18.99M 股
Vanguard Capital Management, LLC 7.03% · 15.25M 股
State Street Global Advisors 4.81% · 10.43M 股
Wellington Management Group 4.25% · 9.21M 股
Vanguard Portfolio Management, LLC 2.87% · 6.21M 股
Other 72.29%
Sanders Capital, LLC 2.69% · 5.83M 股
Geode Capital Management, LLC 2.38% · 5.17M 股
Harris Associates L.P. 2.27% · 4.92M 股
Artisan Partners Limited Partnership 2.11% · 4.58M 股
First Eagle Investment Management, LLC 1.93% · 4.19M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 33次买入 · 17次卖出

姓名职务持股比例
Gail Boudreaux Chief Executive Officer 0.07%
Felicia Norwood Executive VP & President of Government Health Benefits 0.01%
Peter Haytaian Executive VP and President of Carelon & CarelonRx 0.01%
Mark Kaye Chief Financial Officer 0.00%
Blair Todt EVP, Chief Legal & Administrative Officer and Interim Head of HR, Global Security & Safety Team 0.00%
Ramiro Peru Independent Director 0.00%
Erin Wessling EVP & Chief Legal Officer 0.00%
Robert Dixon Independent Director 0.00%
Charles Kendrick Executive VP and President of Commercial & Specialty Health Benefits 0.00%
Ryan Schneider Independent Director 0.00%
Steven Collis Independent Director 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-02 Erin Wessling EVP & Chief Legal Officer Sale to Issuer -349 $405.84–414.78
2026-09-01 Ryan Craig EVP & Chief HR Officer Sale to Issuer -144 $405.84
2026-07-16 Ramiro Peru Independent Director Open Market Acquisition +1,000 $366.05
2026-07-16 Gail Boudreaux Chief Executive Officer Open Market Acquisition +2,725 $366.41–368.25
2026-07-06 Ronal Clark Independent Director Intent to Sell (Form 144) -1,500 $419.91
2026-06-11 Ronald Penczek Chief Accounting Officer Open Market Disposition -369 $403.16
2026-06-10 Robert Dixon Independent Director Open Market Disposition -151 $401.77
2026-05-18 Ronald Penczek Chief Accounting Officer Derivative Exercise and Sale -1,531 $271.27–403.13
2026-05-12 Ramiro Peru Independent Director Other Acquisition +563 --
2026-05-12 Lewis Hay Independent Director Other Acquisition +563 --
2026-05-12 Steven Collis Independent Director Other Acquisition +563 --
2026-05-12 Deanna Strable-Soethout Independent Director Other Acquisition +563 --
2026-05-12 Amy W. Schulman Independent Director Other Acquisition +563 --
2026-05-12 Bahija Jallal Independent Director Other Acquisition +563 --
2026-05-12 Susan DeVore Independent Director Other Acquisition +563 --
2026-05-12 Ryan Schneider Independent Director Other Acquisition +563 --
2026-05-12 Robert Dixon Independent Director Other Acquisition +563 --
2026-05-12 Antonio Neri Independent Director Other Acquisition +563 --
2026-03-11 Amy W. Schulman Independent Director Open Market Disposition -26 $287.50
2026-03-05 Charles Kendrick Executive VP and President of Commercial & Specialty Health Benefits Open Market Disposition -3,196 $284.92

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:30 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

诚信健康 讨论区 0 条评论

发表评论